Evidence map›Paper›PMID 36166456›Full record

ArticlePloS one2022

Modulating myoblast differentiation with RNA-based controllers.

Peter B Dykstra, Thomas A Rando, Christina D Smolke

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Peter B DykstraDepartment of Bioengineering, Stanford University, Stanford, CA, United States of America.ORCID 0000-0002-2626-7104
Thomas A RandoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, United States of America.
Christina D SmolkeDepartment of Bioengineering, Stanford University, Stanford, CA, United States of America.ORCID 0000-0002-5449-8495
Stanford University · USChan Zuckerberg Initiative (United States) · US

Funding

Wnt signaling in muscle stem cell agingP01AG036695 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI THOMAS A. RANDO · 2011 to 2026
$29.3M
Frameworks for programming ligand-responsive RNA regulatory systemsR01GM086663 · NIGMS · STANFORD UNIVERSITY · PI ENDY, DREW · 2009 to 2024
$3.7M
Aging and Stem Cell ResilienceR01AG068667 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RANDO, THOMAS A. · 2021 to 2025
$2.8M
Molecular Regulation of Stem Cell QuiescenceR01AR073248 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RANDO, THOMAS A. · 2018 to 2022
$2.6M
NIAMS NIH HHS R01 AR073248NIA NIH HHS P01 AG036695NIA NIH HHS R01 AG068667NIGMS NIH HHS R01 GM086663
6 · The paper itself

Abstract

Tunable genetic controllers play a critical role in the engineering of biological systems that respond to environmental and cellular signals. RNA devices, a class of engineered RNA-based controllers, enable tunable gene expression control of target genes in response to molecular effectors. RNA devices have been demonstrated in a number of systems showing proof-of-concept of applying ligand-responsive control over therapeutic activities, including regulation of cell fate decisions such as T cell proliferation and apoptosis. Here, we describe the application of a theophylline-responsive RNA device in a muscle progenitor cell system to control myogenic differentiation. Ribozyme-based RNA switches responsive to theophylline control fluorescent reporter expression in C2C12 myoblasts in a ligand dependent manner. HRAS and JAK1, both anti-differentiation proteins, were incorporated into RNA devices. Finally, we demonstrate that the regulation of HRAS expression via theophylline-responsive RNA devices results in the modulation of myoblast differentiation in a theophylline-dependent manner. Our work highlights the potential for RNA devices to exert drug-responsive, tunable control over cell fate decisions with applications in stem cell therapy and basic stem cell biology research.

Indexed as

RNARNA, CatalyticCell DifferentiationLigandsMuscle DevelopmentMyoblastsTheophyllineLigandsRNARNA, CatalyticTheophylline

Identifiers

PMID36166456
PMCPMC9514614
OpenAlexW4297253609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.